Prognostic indicators of recurrence after surgical resection in non-pancreatic gastrointestinal neuroendocrine tumors.

• DOI: 10.1200/jco.2024.42.16_suppl.e16287
• Publication Date: 2024-07-03T19:29:20Z
• Authors: Ian Schonman; Marianna Zahurak; Nirali Marvania; Arielle Rose Urman; Daniel A. Laheru; Jin He; Jonathan Greer; Ana De Jesus-Acosta
• Keywords: Surgical resection

e16287 Background: The incidence of gastrointestinal neuroendocrine tumors (GI-NETs) has continued to increase over the last two decades. In patients with locoregional disease, surgical resection primary tumor without additional therapies is considered standard care. frequency and risk factors associated recurrence survival in non-pancreatic GI-NETs are poorly defined. We aimed evaluate clinical pathological resected GI-NETs. Methods: conducted a retrospective review who presented Johns Hopkins Hospital between 2000-2019 small bowel, colon, appendiceal, rectal underwent curative intent. collected data including site, differentiation, grade using Ki-67 labeling index (grade 1, 2, or 3), margin involvement, perineural vascular invasion, time recurrence, patterns death. Patients metastatic disease at diagnosis insufficient follow up were excluded. Results: A total 133 met inclusion criteria. Most had originating from bowel (n = 87, 66%), followed by appendix 19, 15%), rectum 18, 14%), colon 7, 5%). With median follow-up 35 months, 23 (17%) progression after curative-intent surgery, liver 13, 57%) as most common site. majority patients, well-differentiated 118, 97%) 1 78, 75%). Intermediate/high 2/3) occurred 26 (25%) patients. Median progression-free was 226 months (18.8 years). Age (greater than 60) intermediate/high 2 3) worse overall HR 5.5 (95% CI: 1.5, 19.6), p 0.009, 3.3 1.1, 10.2), 0.034, respectively. Tumor (2 positive nodes 4.5 2.0, 10.1), 4e-04, 3.1 1.4, 6.8), Conclusions: significant number surgery. Risk for include intermediate/high-grade lymph nodes. Further studies needed role adjuvant therapy higher following